Jinan Zhuocheng Bio-Tech Co., Ltd.

When we talk about veterinary medicines, attention is often focused on finished dosage forms used directly to treat animals. Less visible, however, is another group of products that plays a fundamental role behind these medicines: veterinary API intermediates.

They are not APIs themselves, but they are essential building blocks in API manufacturing. Without reliable and consistent intermediates, the production of veterinary APIs would not be possible.

What Are Veterinary API Intermediates?

In simple terms, an API is the active pharmaceutical ingredient in a veterinary medicinal product, while an intermediate is a partially processed compound generated during the synthesis of an API.

Intermediates occupy a critical position between basic chemical raw materials and finished APIs. They connect upstream chemical manufacturing with downstream pharmaceutical production and can have a direct impact on API quality, production costs, and supply stability.

Although intermediates are different from finished APIs and are subject to different regulatory requirements, their quality remains highly important to downstream manufacturers.

Impurities introduced at the intermediate stage can potentially carry over into subsequent production steps and affect the quality profile of the final API. As a result, veterinary pharmaceutical manufacturers often conduct detailed supplier qualification and audits when sourcing critical intermediates.

Two Important Segments: Sulfonamides and Florfenicol

Two areas are particularly relevant when examining the veterinary API intermediate market: sulfonamide intermediates and florfenicol-related intermediates.

Sulfonamides represent one of the established classes of veterinary pharmaceuticals. Products such as sulfadimidine, sulfadiazine, sulfachlorpyridazine sodium, and sulfaquinoxaline sodium have been used in animal health applications for many years.

Behind these APIs is a multi-stage synthesis chain involving a range of chemical intermediates. Depending on the specific product and manufacturing route, compounds such as pyridazine- and pyrazine-related intermediates may play important roles in the synthesis process.

For products such as sulfachloropyrazine sodium, multiple chemical steps—including chlorination, condensation, salt formation, decolorization, and purification—may be involved. The yield and purity of intermediates at each stage can directly influence the manufacturing cost and quality of the final API.

Florfenicol represents another important segment.

As a veterinary amphenicol antibiotic, florfenicol is widely used in animal health applications. Its manufacturing process is closely associated with the key chiral intermediate D-ethyl ester.

Historically, D-ethyl ester production relied heavily on conventional chemical resolution processes, which involved relatively complex processing and significant production costs. Advances in synthetic biology and biocatalysis have introduced alternative approaches, allowing manufacturers to move toward more efficient biotransformation processes.

The resulting improvements can reduce production costs while also supporting better control of intermediate purity.

The impact of this technological development extends beyond the intermediate itself. Lower D-ethyl ester costs can influence the economics of downstream florfenicol production and related products, potentially changing the competitive dynamics of the broader market.

Some industry forecasts estimate that the global D-ethyl ester market could expand from approximately USD 80.1 million in 2024 to USD 209.6 million by 2035, representing a compound annual growth rate of approximately 9.1%.

Environmental Compliance Is Raising the Industry Threshold

Veterinary API intermediates are fundamentally part of the chemical synthesis industry. As a result, environmental compliance has become an increasingly important factor in the development of the sector.

In May 2026, China's Ministry of Ecology and Environment released a draft revision of the Discharge Standard of Water Pollutants for Pharmaceutical Industry—Chemical Synthesis Products for public consultation.

One area attracting particular attention is the proposed clarification and expansion of the scope of application. The draft includes wastewater-discharge entities involved in the production of chemical-synthesis pharmaceutical intermediates exclusively used for pharmaceutical manufacturing, as well as certain veterinary pharmaceutical production activities involving structures similar to chemically synthesized pharmaceuticals.

The proposed revision also introduces additional control parameters, including limits related to total salt content and certain perfluorinated substances, while updating acute toxicity assessment requirements.

For intermediate manufacturers, tighter environmental standards are likely to increase compliance investment.

However, stricter environmental requirements can also accelerate industry consolidation. Smaller manufacturers with limited environmental infrastructure may find it increasingly difficult to absorb the cost of compliance, while larger manufacturers with established environmental management systems may be better positioned to maintain and expand production.

Have Intermediate Prices Reached the Bottom?

Price remains one of the most sensitive variables across the pharmaceutical supply chain.

Veterinary API intermediate prices directly influence the manufacturing costs of downstream APIs and can eventually affect the economics of the wider veterinary pharmaceutical market.

In August 2026, Puluo Pharmaceutical indicated on its investor interaction platform that prices for its veterinary API intermediates had remained at relatively low levels for an extended period and that the potential for further declines was becoming limited.

The company's comments highlighted two major variables for future market conditions: the sustainability of supply-side capacity reductions and the pace of a meaningful recovery in downstream livestock demand.

In other words, the potential recovery of intermediate prices depends on both sides of the market. Supply-side restructuring needs to continue, while demand from the livestock sector needs to recover sufficiently to absorb available capacity.

There are already mixed signals from the market.

For example, Haisheng Pharmaceutical's 2026 interim results showed significant growth in both its API and intermediate businesses, with API revenue increasing by 39.22% year on year and intermediate revenue shifting from a 7.34% decline in 2025 to 42.42% growth. Its intermediate business also reported a gross margin of 46.22%.

These figures may indicate improving demand for certain products and market segments.

At the same time, the overall veterinary API industry remains relatively fragmented. A large proportion of products are generic or non-patented varieties, while product homogenization and intense price competition continue to affect manufacturers.

This combination of fragmented supply, limited product differentiation, and uneven demand recovery remains an important factor influencing intermediate prices.

Technology and Industry Consolidation Are Shaping the Future

Looking at the veterinary API intermediate sector in 2026, several forces are interacting simultaneously.

At the technology level, biocatalysis and synthetic biology are increasingly being applied to processes that were traditionally based on conventional chemical synthesis.

The development of more efficient D-ethyl ester manufacturing processes demonstrates how biomanufacturing technologies can reduce costs and improve process efficiency. Companies that successfully industrialize these technologies may develop meaningful advantages in both manufacturing economics and product consistency.

At the industrial level, vertical integration is becoming increasingly important among larger manufacturers.

Companies with integrated production capabilities can control critical intermediates internally, reduce exposure to external supply fluctuations, improve production planning, and strengthen quality consistency. In periods of significant price volatility, internal intermediate production can provide an additional layer of supply chain resilience.

At the market level, international expansion is becoming another potential growth driver.

For API and intermediate manufacturers, entering regulated international markets requires more than competitive pricing. Regulatory approvals, quality systems, documentation, manufacturing consistency, and international GMP capabilities all become important factors.

Companies capable of meeting requirements associated with markets such as the United States, Europe, and Japan may gain access to higher-value customer segments while strengthening their credibility in the broader international market.

At the regulatory level, stricter requirements are likely to remain a long-term trend.

Environmental standards, veterinary GMP requirements, traceability systems, and controls over veterinary drug production, distribution, and use are gradually creating a more comprehensive compliance framework.

This process may accelerate the restructuring of the intermediate sector and encourage greater concentration among manufacturers with stronger technical, environmental, and quality-management capabilities.

Conclusion

Veterinary API intermediates may receive far less public attention than finished veterinary medicines or APIs themselves, but they occupy a critical position in the animal health supply chain.

Their price fluctuations directly affect downstream manufacturing costs. Their technological development can reshape the competitiveness of individual API products. Their environmental and safety performance can also influence the long-term sustainability of the industry.

For manufacturers, the intermediate sector requires both chemical engineering capabilities and pharmaceutical quality-management capabilities.

The companies best positioned for the next stage of development are likely to be those that can combine process innovation, supply chain integration, cost control, quality consistency, and environmental compliance.

As the veterinary pharmaceutical industry continues to evolve, API intermediates will remain an increasingly important part of the competition for manufacturing efficiency, supply reliability, and long-term market competitiveness.